SCHEMBL3550177

SCHEMBL3550177

COC(=O)c1cc(OC)cc(OC(=O)N(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.48
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
ALDH1A1 P00352 4/20 0.46
PKM P14618 1/20 0.45
KMT2A Q03164 1/20 0.45
ACHE P22303 5/20 0.45
BCHE P06276 2/20 0.45
POLB P06746 2/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CYP2D6 P10635 2/20 0.43
ADRB2 P07550 1/20 0.43
KCNH2 Q12809 1/20 0.43
LMNA P02545 1/20 0.43
CYP2C19 P33261 1/20 0.43
KDM4E B2RXH2 2/20 0.43
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18058841 0.88 RAB9A (0.61) RAB9AALDH1A1PKMKMT2AACHE
SCHEMBL3549497 0.84 CA1 (0.43) RAB9ACA1CA2ALDH1A1KMT2A
Methyl 3,5-Dimethoxybenzoate SCHEMBL204865 0.84 CA1 (0.61) RAB9ACA1CA2ALDH1A1PKM
SCHEMBL19212910 0.81 RAB9A (0.53) RAB9AALDH1A1PKMKMT2AACHE
SCHEMBL16533898 0.81 CA1 (0.50) RAB9ACA1CA2ALDH1A1KMT2A
SCHEMBL4877066 0.80 BCHE (0.40) RAB9AALDH1A1PKMKMT2AACHE
SCHEMBL475746 0.80 CA1 (0.61) RAB9ACA1CA2ALDH1A1PKM
SCHEMBL3554201 0.79 CA1 (0.48) RAB9ACA1CA2ALDH1A1PKM
SCHEMBL3546357 0.78 CA1 (0.44) RAB9ACA1CA2ALDH1A1KMT2A
SCHEMBL9970808 0.78 KMT2A (0.53) RAB9AALDH1A1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE RAB9A 3256/4885CA1 4363/4885CA2 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.